新世界购物与武清区龙济医院男科医院近吗(天津武清龙济医院男子医院主页) (今日更新中)

The Broadway League, the trade association that regulates theater performances in New York City, said Monday that all Broadway shows would be canceled through the end of 2020 due to the coronavirus pandemic.The group says that those who have purchased tickets to shows before Jan. 3, 2021 will automatically receive an email detailing refund and exchange information."Every single member of our community is eager to get back to work sharing stories that inspire our audience through the transformative power of a shared live experience," Thomas Schumacher, the Broadway League's Chairman of the Board, said in a statement released Monday. "The safety of our cast, crew, orchestra and audience is our highest priority and we look forward to returning to our stages only when it’s safe to do so. One thing is for sure, when we return we will be stronger and more needed than ever.”“Our membership is working closely with the theatrical unions and in concert with key experts and some of the greatest minds inside and outside of the industry to explore protocols for all aspects of reopening. We are focused on identifying and implementing necessary measures that will enable us to resume performances safely for Broadway audiences and employees,” Charlotte St. Martin, the president of the Broadway League, said in a statement. “We are determined to bring back the people who rely on this industry for their livelihood, and to welcome back all those who love this vital part of New York City, as soon as it is safe to do so. "Broadway performances in New York shut down on March 12, the day before President Donald Trump declared the pandemic a national emergency. Last month, the Broadway League said it was canceling all performances through Sept. 6. 1759

The CEO of a skincare company has issued an apology after she accused a man of "defacing private property" by chalking the words "Black Lives Matter" on the building where he lives in San Francisco.The CEO of LAFACE skincare, Lisa Alexander, issued a public apology to James Juanillo, the man she accosted."The last 48 hours has taught me that my actions were those of someone who is not aware of the damage caused by being ignorant and naive to racial inequalities. When I watch the video I am shocked and sad that I behaved the way I did. It was disrespectful to Mr. Juanillo and I am deeply sorry for that," Alexander's statement read, in part.The video, posted to social media on Friday, shows Alexander and another man, later identified as Robert Larkin, speaking with Juanillo. In the video, Alexander accuses Juanillo of "defacing private property" as he stenciled "Black Lives Matter" in yellow chalk on a wall at his home.Alexander and Larkin told Jaunillo that he was "free to express his opinion," but "that was not the way to do it."Juanillo then asked if it would be OK if he were chalking his own property. Alexander and Larkin said that they knew Juanillo didn't own the property because they "knew who lived there."Juanillo encouraged Alexander and Larkin to call the police if they felt unsafe. Juanillo told KGO in San Francisco that the two did call the police, but when officers arrived, they quickly recognized Juanillo as a resident."I didn't even show (the police) my ID," Juanillo told KGO.KGO also spoke to one of the property owners, who said he does not know Alexander or Larkin.The video of the incident spread quickly on social media, with many referring to Alexander as a "Karen" — a slang term for an entitled woman, often used in the context of racism.Alexander's identity was not independently confirmed until she came forward to apologize. However, Birchbox — a makeup subscription service — released a statement on Twitter denouncing Alexander's actions after Twitter users brought the video to their attention. Birchbox said that it had not worked with LAFACE in "several years," but nonetheless had "officially cut ties with the company."The video also prompted trolls to leave negative Yelp reviews of a Los Angeles-based skincare store, My LA Face, which has no connection to Alexander or her business, LAFACE. A representative for Yelp told KGO that those negative reviews would be removed.Read Alexander's full statement below.I want to apologize directly to Mr. Juanillo. There are not enough words to describe how truly sorry I am for being disrespectful to him last Tuesday when I made the decision to question him about what he was doing in front of his home. I should have minded my own business.The last 48 hours has taught me that my actions were those of someone who is not aware of the damage caused by being ignorant and naive to racial inequalities. When I watch the video I am shocked and sad that I behaved the way I did. It was disrespectful to Mr. Juanillo and I am deeply sorry for that. I did not realize at the time that my actions were racist and have learned a painful lesson. I am taking a hard look at the meaning behind white privilege and am committed to growing from this experience. I would love to have coffee with Mr. Juanillo in our neighborhood so I can apologize in person and share a dialogue where I can continue to learn and grow and be a better person.Robert Larkin also issued an apology statement.Over the last two days, I have had my eyes opened wide to my own ignorance of racial inequity, and I have thought a lot about my own personal blind spots. I was wrong to question Mr. Juanillo, and I was wrong to call the neighborhood police watch. It was wrong, and I am profoundly sorry for treating him with disrespect.I have a lot to learn about how racism impacts people in their lives, daily, I have hurt my neighbor. I am full of regret and very sorry. I am hoping to meet with him soon to express my sincere apology and to ask for his forgiveness and guidance in helping me begin the journey towards being a kinder, more thoughtful and sensitive person. 4144

The Food and Drug Administration (FDA) has cleared the way for a generic version of EpiPen to be created.The FDA’s approval for a generic version, which will be created by Teva Pharmaceuticals, could help alleviate issues like high cost for the life-saving allergy medication.Two year ago, prices for EpiPens skyrocketed, as manufacturer Mylan raised rates from less than 0 for a two-pack to close to 0.But new action by the FDA paves the way for a generic form of the drug, so pharmacies can now offer a generic form to customers, without having to call the doctor to write a new prescription."Oh, it's a huge deal for consumers because the current price is astronomical for a drug that you hope never to use,” says Gerard Anderson, a professor at Johns Hopkins University who has testified about drug prices before Congress.EpiPens have been experiencing shortages, made even worse by the back-to-school orders placed by parents. Anderson says this move to create generic forms should help with the supply and bring prices down.“You’re still gonna get the same drug administered,” says Anderson of the generic forms of the medication. “And so, as a consumer, as a parent, I would choose a less expensive alternative.” 1233

The E.W. Scripps Company, based in Cincinnati, Ohio announced it has added two television stations to its business, bringing its current total to 35 stations in 26 markets.The stations purchased are ABC affiliates KXXV/KRHD in Waco, Texas, and WTXL in Tallahassee, Florida. Both were owned by Raycom Media."These two stations are strategic additions to our portfolio," said Brian Lawlor, President, Local Media."We have been interested in expanding into Texas for some time as we believe Texas will play an important part in U.S. politics moving forward," Lawlor said of the KXXV/KRHD purchase.Scripps owns WFTS in Tampa, WFTX in Fort Myers and WPTV in West Palm Beach, making WTXL its fourth in the state."The addition of Tallahassee will allow us to better cover the state's politics as we expand our reach beyond 50 percent of Florida’s television households," Lawlor said in a memo to Scripps employees.The announcement follows Scripps’ news Aug. 15 that it has completed the sale of its 34 radio stations for .5 million.Scripps' stations are affiliated with all of the Big Four television networks: ABC, NBC, CBS and FOX. The purchase of the two new stations adds 130 employees to The E.W. Scripps Company and brings it to 17 ABC affiliates. 1277

The Food and Drug Administration says it is re-examining the safety of a medication that was approved despite concerns that not enough was known about the drug's risks.In response to questioning at a budget hearing last week, FDA Commissioner Scott Gottlieb told members of Congress that he would "take another look" at Nuplazid, which is the only drug approved to treat hallucinations and delusions associated with Parkinson's disease psychosis.The medication has been cited as a so-called "suspect" medication in hundreds of deaths voluntarily reported by caregivers, doctors and other medical professionals since it hit the market, as highlighted in a recent CNN report.The FDA told CNN this week that the agency had already begun conducting a new evaluation of the medication when Gottlieb was questioned about it at the hearing. The agency said the review had started several weeks ago."What does it take for a drug like this to be taken off the market?" asked US Rep. Rosa DeLauro, a member and former chair of the congressional subcommittee responsible for funding and overseeing the FDA.DeLauro pressed Gottlieb for answers on his agency's response to the safety concerns surrounding Nuplazid."How many more adverse events do we have to have reported? How many people, quite frankly, have to die? Why does the industry always take precedence over public health and safety?"Tracked by the FDA, the adverse event reports cited by DeLauro do not mean that a suspected medication has been ruled the cause of harm and are typically not the result of official investigations. But the FDA uses the information to monitor potential issues with a drug and can take action as needed: updating a medication's label, for instance, or restricting its use. In rare cases, the agency can even pull a drug off the market.When asked by CNN about what prompted the FDA's new evaluation of Nuplazid, the agency said the decision was based on a number of factors but wouldn't say what those factors were. Instead, it would only comment generally, saying that it identifies "potential signals of serious risk/new safety information" in part by using adverse event data and that the agency is not suggesting physicians stop prescribing the drug or take patients off of it while a safety evaluation is taking place.The FDA has noted that the death reports citing Nuplazid have typically involved elderly patients with advanced-stage Parkinson's disease who suffered from numerous medical conditions and often take other medications that can increase the risk of death.But physicians, researchers and other medical experts told CNN that the high number of reports deserved a closer look to determine whether they were related to the drug. They also recommended further testing of Nuplazid, worrying that the drug had been approved too quickly, based on too little evidence that it was safe or effective.Nuplazid's review was expedited by the FDA because it had been designated a "breakthrough therapy," meaning it demonstrated "substantial improvement" in patients with serious or life-threatening diseases compared to treatments already on the market.Dr. Paul Andreason, the physician who led the FDA's medical review of Nuplazid, warned that patients taking the drug during the company's clinical trials experienced serious outcomes, including death, at more than double the rate of those taking the placebo. But the FDA ruled that the potential benefits outweighed the risks, agreeing with an advisory committee that cited a lack of safe alternatives and the pleas from family members who claimed the drug was already helping or could help their loved ones.At that advisory committee meeting two years ago, one woman said that her grandmother had been part of the clinical trials for the drug and that Nuplazid had been life-changing."We didn't know what to expect or even if she was on the drug" or a placebo, said Zoey Wade. "We soon realized that she must be taking the drug, because she really returned to herself. Her hallucinations reduced, and she better understood what was real and what was imaginary."Shortly after Nuplazid's release, however, patients' family members, doctors and other health care professionals started reporting "adverse events" possibly linked to the medication -- including deaths, life-threatening incidents, falls, insomnia, nausea and fatigue.During the first 10 months Nuplazid was on the market, 244 deaths were reported to the FDA in which Nuplazid was a "suspect" medication, according to an analysis conducted by the Institute for Safe Medication Practices. FDA data now show that the number of reported deaths has risen to more than 700. In more than 1,000 reports, patients continued to experience hallucinations while on Nuplazid.After CNN published its investigation on Nuplazid, reporters were contacted by family members who said the drug helped tame hallucinations with few apparent side effects and others who said they believe Nuplazid contributed to their family member's decline or death. Some said they had not yet reported these experiences to the drugmaker or the FDA.While the FDA has long been criticized for being too slow to approve drugs, DeLauro seized on its push to streamline the process, lambasting the agency for putting industry interests and efficiency above public health and safety.DeLauro described the number of adverse events and deaths as "staggering" and "unprecedented." She also expressed concern that the drugmaker, Acadia Pharmaceuticals, is attempting to get the drug approved for a larger population: patients who suffer from dementia-related psychosis."I don't know why it should stay on the market, especially when the FDA has not determined it to be safe and while the number of adverse events continues to soar," she told Gottlieb.In response to the congresswoman's remarks, Acadia told CNN that adverse event data alone are "not a comprehensive and accurate indicator of the safety profile of any drug." In response to CNN's earlier report on the drug, Acadia said there are a number of reasons for the higher volume of death reports, including the fact that the company distributes Nuplazid through a network of specialty pharmacies that puts the company in more frequent contact with both patients and caregivers -- meaning Acadia is more likely to receive reports of death, which it is required to pass along to the FDA.Commissioner Gottlieb told the committee that the FDA is careful about the decisions it makes and that there may be a higher tolerance for risk in situations where there is an unmet medical need, "so long as the patient is properly informed of what those risks are." This echoed what he told CNN's Dr. Sanjay Gupta in an interview earlier this month.The FDA previously told CNN that it was aware of Nuplazid's "complex safety profile" at the time of approval and required the drugmaker to place warnings on its labeling. The agency also said that, though it was continuing to monitor available information about Nuplazid, it had "not identified a specific safety issue" not already reflected on the medication's label.DeLauro's office told CNN that it plans to follow up with the FDA about its inquiry into Nuplazid. 7224

来源：资阳报